Valuation depends on cash flow and pipeline. Currently the later has little value only because SPPI has no proven track record of resurrecting fallen angels.which they buy from other Pharmas.
The run up to +$17 was based on Fusilev sales . IMO that chapter is now over and the stock is likeley to revert to its pre Fusilev valuations closer to the $5 level.
Many will consider that level is too low and they may be right. Good luck.!
sorry but this was a PENNY STOCK in 2008.. with Raj's credibility BEWARE.. if they have to RESTATE because of ACCOUNTING ERRORS.. who knows? everything is OUT THE WINDOW.. along with the SHAREHOLDERS MONEY.. get it?